Publications by authors named "Ned Rupp"
Background: Due to limited treatment options for peanut allergy, patients remain at risk for allergic reactions due to accidental exposure. Epicutaneous immunotherapy (EPIT) is a novel treatment being investigated for peanut allergy.
Objective: This study assessed long-term safety of EPIT with VIASKIN® peanut patch 250 μg (VP250) via an open-label extension of the REAL Life Use and Safety of EPIT (REALISE) trial.
Background: Treatment options for peanut allergy are limited. In previous clinical trials, epicutaneous immunotherapy with a patch containing 250-μg peanut protein (Viaskin Peanut 250 μg [VP250]) was well tolerated and statistically superior to placebo in desensitizing peanut-allergic children.
Objective: To examine the safety of VP250 in children, using a study design approximating potential real-world use.
Article Synopsis
- The ARC004 study explored the long-term effects and various dosing regimens of daily oral immunotherapy with Peanut allergen powder (PTAH) in peanut-allergic children and adolescents, following positive results from the PALISADE trial.
- A total of 358 participants, both those who had continued from the PALISADE trial and new participants, underwent different daily or non-daily dosing strategies, with safety and efficacy being assessed.
- Results indicated that daily dosing led to higher desensitization rates with sustained safety, and the immune response continued to show signs of improvement in participants over the course of the study.
Background: Peanut allergy, for which there are no approved treatment options, affects patients who are at risk for unpredictable and occasionally life-threatening allergic reactions.
Methods: In a phase 3 trial, we screened participants 4 to 55 years of age with peanut allergy for allergic dose-limiting symptoms at a challenge dose of 100 mg or less of peanut protein (approximately one third of a peanut kernel) in a double-blind, placebo-controlled food challenge. Participants with an allergic response were randomly assigned, in a 3:1 ratio, to receive AR101 (a peanut-derived investigational biologic oral immunotherapy drug) or placebo in an escalating-dose program.
Background: Few studies have assessed the safety and efficacy of potential asthma medications in children younger than 5 years. We descriptively assessed the safety and efficacy of tiotropium, a long-acting anticholinergic drug, in children aged 1-5 years with persistent asthmatic symptoms.
Methods: This exploratory 12-week, randomised, double-blind, placebo-controlled, parallel-group, phase 2/3, regulatory multicentre trial was done at 32 hospitals, clinics, and clinical research units in 11 countries in Asia, Europe, and North America.
Background: Exercise is a common trigger of asthma symptoms in patients with persistent asthma.
Objective: To evaluate the protective effect of fluticasone/salmeterol against exercise-induced bronchospasm.
Methods: Multicenter, randomized, double-blind, parallel-group trial of 192 asthma patients who used moderate-dose inhaled corticosteroids.